The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: The final analysis of cohort 1.
 
Rino S. Seedor
No Relationships to Disclose
 
Marlana M. Orloff
Consulting or Advisory Role - IDEAYA Biosciences; Immunocore; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Linnaeus Therapeutics (Inst); Plexxikon (Inst)
 
Erin Sharpe-Mills
No Relationships to Disclose
 
Liam Hulse
No Relationships to Disclose
 
Reshma Shelat
No Relationships to Disclose
 
Ayako Shimada
No Relationships to Disclose
 
Inna Chervoneva
No Relationships to Disclose
 
Carol L. Shields
Consulting or Advisory Role - Aura Biosciences
 
Jerry A. Shields
No Relationships to Disclose
 
Michael J. Mastrangelo
No Relationships to Disclose
 
Takami Sato
Consulting or Advisory Role - Castle Biosciences; Immunocore
Research Funding - Immunocore (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Castle Biosciences